Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib plus best supportive care versus placebo in previously EGFR TKI-treated advanced non-small cell lung cancer
2006-002384-12Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing ZACTIMA plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: overall survival. Started Sep 2006; status: completed.
02
Drugs
vandetanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-002384-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002384-12.